NYXOAH S A Stock Price, News & Analysis

On September 12, 2021, Nyxoah SA disclosed the issuance of 1,400,000 new warrants and 82,500 new shares. Following these events, the company's share capital has reached EUR 4,384,076.09 and the total number of securities carrying voting rights is now 25,520,359, all ordinary shares. The number of outstanding subscription rights includes various ESOP warrants issued between 2013 and 2021, entitling holders to subscribe to a total of 1,721,500 additional voting rights. This update is aligned with the Law of 2 May 2007 on large shareholdings.

Nyxoah SA (Nasdaq: NYXH) announced its participation in the Baird 2021 Global Healthcare Conference, scheduled for September 14, 2021. CEO Olivier Taelman and CFO Fabian Suarez will present virtually at 3:05 pm CET / 9:05 am ET. Nyxoah specializes in innovative solutions for Obstructive Sleep Apnea (OSA), with its leading product, the Genio® system, receiving CE Mark approval in 2019 following successful clinical trials. The company is currently conducting the DREAM IDE pivotal study for FDA approval and a European study to confirm the Genio® system's long-term effectiveness.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced on September 1, 2021, that it received transparency notifications from Robelga SRL and Together Partnership regarding their shareholdings. Robelga SRL's shareholding fell below 3%, holding 696,000 shares (2.78% of voting rights) as of July 7, 2021. Meanwhile, Together Partnership reported a downward crossing of the 10% threshold, holding 2,503,500 shares (9.84% of voting rights) as of July 9, 2021. The total voting rights for these entities combined represent 11.27% of all voting rights in Nyxoah.

Nyxoah reported its first half 2021 financial results, highlighting gross proceeds of $97.8 million from its Nasdaq IPO and €355 thousand in revenue, a notable increase from zero in the same period last year. The company is actively expanding its commercial presence in Germany, reporting 12 active accounts in Q2, up from 2 in Q1 2021. However, it recorded a net loss of €12.6 million compared to €4.3 million in the previous year, attributed mainly to heightened operational expenses across various departments. The cash position improved to €79.2 million.

Nyxoah has announced the appointment of Rita Johnson-Mills as an Independent Director to its Board, effective immediately. Her extensive background includes over 30 years in healthcare, notably as CEO of UnitedHealthcare Community Plan of Tennessee. The Chairman, Robert Taub, highlighted her experience and governance expertise as vital for Nyxoah's growth in the healthcare industry. Johnson-Mills aims to enhance Nyxoah's board diversity and strengthen its presence in the U.S. market, while the company focuses on innovative solutions for Obstructive Sleep Apnea treatment.

Nyxoah SA (Nasdaq: NYXH) announced its plan to release financial results for the first half of 2021 on August 31, 2021, after US markets close. A conference call will be held on September 1, 2021, at 3:00 p.m. CET to discuss these results. The company focuses on innovative solutions for treating Obstructive Sleep Apnea (OSA) and has made progress with its Genio® system, which received European CE Mark approval in 2019. Nyxoah is currently conducting pivotal studies for FDA approval and further research on the therapy's long-term efficacy.

On July 19, 2021, Nyxoah SA (NASDAQ: NYXH) announced a transparency notification from BNP Paribas Asset Management SA, revealing a passive downward crossing of the 3% threshold in voting rights. As of July 7, 2021, BNP Paribas held 696,562 shares, equivalent to 2.79% of total voting rights (25,002,609). The notification indicates changes in shareholding but does not indicate any active trading or strategic decisions impacting the company’s operations.

Nyxoah SA, a medical technology company, announced on July 14, 2021, it received a transparency notification from Deerfield Partners, L.P. The notification, received on July 12, detailed that Deerfield acquired 899,300 shares on July 7, 2021, crossing the 3% voting rights threshold, now holding 3.60% of the total voting rights. This acquisition reflects Deerfield’s growing investment in Nyxoah, indicating confidence in the company’s future prospects.

Nyxoah SA announced the issuance of 435,250 new shares on July 9, 2021, following a capital increase tied to its IPO in the U.S. and the exercise of subscription rights. The total share capital now stands at EUR 4,369,902.59, resulting in 25,437,859 voting rights from ordinary shares. Additionally, there are outstanding rights to subscribe to 927,500 shares through various ESOP warrants.